Nuvation Bio Inc (NYSE: NUVB) kicked off on Friday, up 14.04% from the previous trading day, before settling in for the closing price of $3.42. Over the past 52 weeks, NUVB has traded in a range of $1.54-$3.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -49.14% over the last five years. While this was happening, its average annual earnings per share was recorded 69.19%. With a float of $230.22 million, this company’s outstanding shares have now reached $336.84 million.
Nuvation Bio Inc (NUVB) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nuvation Bio Inc is 32.93%, while institutional ownership is 53.52%. The most recent insider transaction that took place on Jun 18 ’25, was worth 17,100. In this transaction CHIEF PEOPLE OFFICER of this company bought 10,000 shares at a rate of $1.71, taking the stock ownership to the 29,591 shares. Before that another transaction happened on Jun 17 ’25, when Company’s Chief Financial Officer bought 4,000 for $1.79, making the entire transaction worth $7,160. This insider now owns 9,902 shares in total.
Nuvation Bio Inc (NUVB) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.12 earnings per share (EPS), lower than consensus estimate (set at -0.1) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 40.81% during the next five years compared to -49.14% drop over the previous five years of trading.
Nuvation Bio Inc (NYSE: NUVB) Trading Performance Indicators
Take a look at Nuvation Bio Inc’s (NUVB) current performance indicators. Last quarter, stock had a quick ratio of 9.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 93.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.63, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Nuvation Bio Inc (NUVB)
Analysing the last 5-days average volume posted by the [Nuvation Bio Inc, NUVB], we can find that recorded value of 9.2 million was better than the volume posted last year of 4.42 million. As of the previous 9 days, the stock’s Stochastic %D was 89.58%.
During the past 100 days, Nuvation Bio Inc’s (NUVB) raw stochastic average was set at 92.46%, which indicates a significant increase from 87.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.22 in the past 14 days, which was higher than the 0.18 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.49, while its 200-day Moving Average is $2.35. Now, the first resistance to watch is $4.17. This is followed by the second major resistance level at $4.44. The third major resistance level sits at $4.79. If the price goes on to break the first support level at $3.55, it is likely to go to the next support level at $3.20. Now, if the price goes above the second support level, the third support stands at $2.93.
Nuvation Bio Inc (NYSE: NUVB) Key Stats
The company with the Market Capitalisation of 1.34 billion has total of 342,273K Shares Outstanding. Its annual sales at the moment are 7,870 K in contrast with the sum of -567,940 K annual income. Company’s last quarter sales were recorded 4,830 K and last quarter income was -59,010 K.
